Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-29
2008-07-29
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S262000
Reexamination Certificate
active
07405220
ABSTRACT:
Novel pyrazolopyrimidines of formula (I):are discussed. These pyrazolopyrimidines are capable of inhibiting the activity of cyclin-dependent kinases, most particularly cyclin-dependent kinase 1 (Cdk1), cyclin-dependent kinase 2 (Cdk2), and cyclin-dependent kinase 4 (Cdk4) and are thus useful, inter alia, in the treatment or control of cancer, in particular solid tumors. This invention also provides pharmaceutical compositions containing such compounds and to methods of treating or controlling cancer, most particularly the treatment or control of breast, lung, colon and prostate tumors.
REFERENCES:
patent: 5654307 (1997-08-01), Bridges et al.
patent: 6107305 (2000-08-01), Misra et al.
patent: 2002/0198171 (2002-12-01), Schinazi et al.
patent: 2005/0203091 (2005-09-01), Arora et al.
patent: WO 91/18887 (1991-12-01), None
patent: WO 99/21845 (1999-05-01), None
patent: WO 00/12485 (2000-03-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 01/19825 (2001-03-01), None
patent: WO 01/38315 (2001-05-01), None
patent: WO 01/79198 (2001-05-01), None
patent: WO 01/64653 (2001-09-01), None
patent: WO 01/64654 (2001-09-01), None
patent: WO 01/64656 (2001-09-01), None
patent: WO 02/057261 (2002-07-01), None
patent: WO 02/090360 (2002-11-01), None
patent: WO 03/097048 (2003-11-01), None
patent: WO 2004/069139 (2004-08-01), None
patent: WO 2004/087707 (2004-10-01), None
Kim et al. KR 2004026462, CAS abstract, Mar. 31, 2004.
Carlson et. al.,Cancer Res.. 1996, 56, 2973-2978.
De Azevedo et al.,Eur. J. Biochem., 1997, 243, 518-526.
Bridges, A.J.,Exp. Opin. Ther. Patents. 1995, 5, 12451257.
Orr et al.,J. Biol. Chem. 1998, 273, 3803-3807.
Kakeya, H. et. al.,Cancer Res.. 1998, 58, 704-710.
Harper, J.W.,Cancer Surveys1997, 29, 91-107.
Harrington, E.A., et al.,Proc. Natl. Acad. Sci. USA1998, 95, 11945-11950.
Leostim, et al.,Eur. J. Biochem.(FEBS) 2000, 267, 5983-5994.
Garrett, M.D. et. al.,Current Opin. Genetics Develop. 1999, 9, 104-111.
McBonyebi, O. P. et al.,Cancer Res.. 1999, 59, 1903-1910.
Hoessel et al.,Nature Cell Biology. 1999, 1, 60-67.
Zaherevitz et al.,Cancer Res., 1999, 59, 2566-2569.
Sielecki, T.M., et al.,Bioorg. Med. Chem. Lett. 2001, 11, 1157-1160.
Nugiel, D. A., et al.,J. Med. Chem., 2001, 44, 1334-1336.
Fry, D. W. et al.,J. Biol. Chem. 2001, 276, 16617-16623.
Soni, R., et al.,Biochem. Biophys. Res. Commun. 2000, 275, 877-884.
Ryu, C-K. et al.,Bioorg. Med. Chem. Lett., 2000, 10, 461-464.
Jeong, H-W., et al.,Bioorg. Med. Chem. Lett.. 2000, 10, 1819-1822.
Barvian et al.,J. Med. Chem., 2000, 43, 4606-4616.
Chong, W., Fischer,Curr. Opin. in Drug Discov. and Develop., 2001, 4, 623-634.
Harris, W. and Wilkinson, S.,Emerging Drugs. 2000, 5, 287-297.
Dumas, J.,Exp. Opin. Ther. Patents. 2001, 11, 405-429.
Sielecki T., et. al.,J. Med. Chem.. 2000, 43, 1-18.
Ding Qingjie
Jiang Nan
Roberts John Lawson
Hoffmann-La Roche Inc.
Johnston George W.
Kifle Bruck
Rocha-Tramaloni Patricia S.
LandOfFree
Pyrazolopyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2784524